Effect of EBV Serology-based Screening Program on NPC Mortality: A Cluster Randomized Controlled Trial

Author:

Chen Wen-Jie,Yu Xia,Lu Yu-Qiang,Pfeiffer Ruth M.,Ling Wei,Xie Shang-Hang,Wu Zhi-Cong,Li Xue-Qi,Fan Yu-Ying,Wu Biao-Hua,Wei Kuang-Rong,Rao Hui-Lan,Huang Qi-Hong,Guo Xiang,Sun Ying,Ma Jun,Liu Qing,Hildesheim Allan,Hong Ming-Huang,Zeng Yi-Xin,Ji Ming-Fang,Liu Zhi-wei,Cao Su-Mei

Abstract

AbstractPurposeTo estimate the effectiveness of an Epstein–Barr virus (EBV) serology-based screening program to reduce nasopharyngeal carcinoma (NPC) mortality in a cluster randomized controlled trial in an NPC high-risk population.MethodsSixteen towns in Sihui and Zhongshan Cities, China were selected; eight were randomly allocated to the screening group and eight to the control group. Cantonese residents aged 30-69 years with no history of NPC were included January 1, 2008 to December 31, 2015. Residents in the screening towns were invited to undergo serum EBV VCA/EBNA1 IgA antibody tests; others received no intervention. Screening lasted through December 31, 2015; the population was followed through December 31, 2017.ResultsA total of 175,037 residents in the screening group and 184,526 residents in the control group were included. NPC incidence was similar in screening and control groups. A 28% reduction in NPC mortality was observed in the screening versus control arms in the overall study population (8.0 NPC deaths per 1000 person years versus 11.1; adjusted rate ratio [aRR]=0.72; 95% confidence interval=0.48-1.09; p=0.12). A stronger benefit was observed among individuals aged >50 (aRR=0.63; p=0.048) compared to those <50 (aRR 0.93; p=0.75). The reduction was increased among individuals from towns randomized to screening who participated in the screening program (aRR=0.38, p=0.001).ConclusionIn this near 10-year trial, serology EBV VCA and EBNA1 IgA antibody testing led to a reduction in NPC mortality, particularly among individuals aged ⩾50. EBV antibody-based screening for NPC is effective at reducing NPC mortality in high-risk populations.Trial registration numberNCT00941538

Publisher

Cold Spring Harbor Laboratory

Reference29 articles.

1. Ferlay J EM , Lam F , Colombet M , Mery L , Piñeros M , Znaor A , Soerjomataram I , Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [08 04 2022].

2. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment;European journal of cancer,2017

3. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study);Oral oncology,2018

4. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma

5. Epidemiology of nasopharyngeal carcinoma

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3